Friday, July 4, 2025

The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By Editorial Team

FDA Approved label on a blue background representing the March 2025 approval of durvalumab for muscle-invasive bladder cancer

FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer

FDA Approved label representing the March 2025 approval of cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors

FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors

The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1

2025-03-21